Welcome to our dedicated page for Corvus Pharmaceuticals SEC filings (Ticker: CRVS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Corvus Pharmaceuticals's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Corvus Pharmaceuticals's regulatory disclosures and financial reporting.
State Street Corporation, through its investment management subsidiaries, reports beneficial ownership of common stock of Corvus Pharmaceuticals, Inc..
State Street reports beneficial ownership of 4,474,091 shares of Corvus common stock, representing 5.3% of the class. It has shared voting power over 4,373,218 shares and shared dispositive power over 4,474,091 shares, with no sole voting or dispositive power.
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company advancing soquelitinib, ciforadenant and mupadolimab. For the quarter ended June 30, 2026, it reported a net loss of $18.0 million, and a $31.7 million net loss for the first half of 2026, reflecting higher research and development expenses of $27.1 million and general and administrative expenses of $7.0 million as clinical programs expanded.
Liquidity strengthened significantly: as of June 30, 2026, Corvus held $215.2 million in cash, cash equivalents and marketable securities, aided by a January 2026 follow-on public offering that raised net proceeds of $189.4 million. An amended at-the-market equity program provides up to $200.0 million of additional potential capacity, with no sales yet under this facility. Management believes current resources will fund planned operations for at least 12 months but anticipates the need for further capital to bring programs through commercialization.
The company continues to invest in its 48–49% equity stake in Angel Pharmaceuticals, contributing $5.0 million in a June 2026 financing and recording a $1.3 million share of Angel’s losses for the first half of 2026. Clinical highlights include an ongoing potentially registrational Phase 3 trial of soquelitinib in relapsed peripheral T cell lymphoma and a Phase 2 trial in atopic dermatitis following encouraging Phase 1 efficacy and safety data.
Corvus Pharmaceuticals, Inc. reported that it issued a press release on August 6, 2026 covering its financial results for the three and six months ended June 30, 2026, its financial position as of June 30, 2026, and a broader business update.
The press release is furnished as Exhibit 99.1. Corvus states that the information related to these results and the exhibit is being furnished, not filed, for purposes of Section 18 of the Securities Exchange Act of 1934 and will only be incorporated into other securities law filings by specific reference.
BlackRock, Inc. filed an amended Schedule 13G reporting a passive ownership stake in Corvus Pharmaceuticals, Inc. common stock. BlackRock reports 6,325,157 shares beneficially owned, representing 7.5% of the outstanding common stock. It has sole voting power over 6,217,422 shares and sole dispositive power over 6,325,157 shares, with no shared voting or dispositive power. Various underlying clients have economic rights to dividends or sale proceeds, but no single client holds more than five percent of Corvus’s total outstanding common shares.
Corvus Pharmaceuticals, Inc. reported that director Ian T. Clark delivered notice on July 21, 2026 of his intention to resign from the company’s board of directors, effective July 22, 2026. The company acknowledged and thanked Mr. Clark for his significant contributions during over nine years of board service.
Corvus Pharmaceuticals director David Scott Moore reported buying shares and receiving stock options. He completed an open-market purchase of 21,700 shares of Common Stock at an average price of $11.5316 per share, and now holds 21,700 common shares directly.
He was also granted a stock option for 15,000 shares of Common Stock at an exercise price of $11.60 per share. The option vests in full on the earlier of the first anniversary of the grant date or the date of Corvus Pharmaceuticals’ 2027 Annual Meeting of stockholders, assuming continuous service as a director until that vesting date.
Corvus Pharmaceuticals director Ian T. Clark received a grant of stock options covering 15,000 shares of common stock. The options have an exercise price of $11.60 per share and expire on June 11, 2036, representing compensation rather than an open-market purchase.
The underlying shares vest and become exercisable in full on the earlier of the first anniversary of the grant date or the company’s 2027 annual stockholder meeting, assuming he continues serving as a director through that date. After this grant, Clark holds stock options for 15,000 shares from this award.
Corvus Pharmaceuticals director Linda Grais received a grant of stock options as equity compensation. The Form 4 shows an award of 15,000 options to buy Common Stock at an exercise price of $11.6000 per share, expiring on June 11, 2036.
The underlying 15,000 shares vest and become exercisable 100% on the earlier of the first anniversary of the grant date or the company’s 2027 Annual Meeting of stockholders, assuming she continues to serve as a director through that vesting date.
Corvus Pharmaceuticals director Peter A. Thompson reported a grant of stock options covering 15,000 shares of Common Stock. The options have an exercise price of $11.6000 per share and expire on June 11, 2036. They vest in full on the earlier of the first anniversary of the grant date or the date of Corvus’ 2027 annual stockholders’ meeting, assuming continuous board service through that date. Under an agreement with OrbiMed Advisors LLC and OrbiMed Capital GP V LLC, any securities or economic benefits from these options are to be provided to OrbiMed Private Investments V, LP, and Thompson disclaims beneficial ownership except to any pecuniary interest.
Corvus Pharmaceuticals director Richard van den Broek received a new stock option grant. On the reported date, he was awarded options to buy 15,000 shares of Corvus common stock at an exercise price of $11.60 per share. All 15,000 options vest in a single tranche on the earlier of the first anniversary of the grant or the company’s 2027 annual stockholder meeting, assuming he continues serving as a director until that vesting date.